Local management of pancreatic carcinoma: iodine-125 implantation.
A retrospective review of patients with pancreatic carcinoma treated from 1983 to 1986 was performed. Group 1 comprise 11 patients judged surgically unresectable who were implanted with iodine-125 followed by external beam therapy post-operatively (Implant + XRT). Eight patients received external beam therapy alone (XRT) Group 2, and 23 patients underwent radical surgical resection (group 3). Median survival was 8 months in the implant + XRT group; 5 months in the XRT alone group and 7.5 months in the surgical group. Locoregional control was achieved in 8/11 (73%), 2/8 (25%), and 11/23 (48%) of these groups respectively. Pain was the most common presenting symptom, 38/42 (90%). Complete, lasting palliation was achieved in 8/10 (80%) of group one, 2/8 (25%) of group two, and 13/20 (65%) of group three patients. Despite surgical unresectability implant + XRT appears to offer similar results to radical surgery. The data are presented with respect to the implant technique, disappearance of the tumour on CT scan and patterns of failure.
Goertz
S R
SR
Department of Radiation Oncology, Medical College of Virginia, Richmond.
Ali
M M
MM
Parker
G A
GA
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002768:Choledochostomy; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate
D007457:Iodine Radioisotopes